Emerging retatrutide, a dual -action medication targeting simultaneously GLP-1 and GIP receptors, is creating considerable interest within the medical community. Initial clinical trials have shown substantial decreases in physical size and advancements in health markers for people with overweight. Researchers believe this unique approach may repres